<DOC>
	<DOCNO>NCT02827513</DOCNO>
	<brief_summary>The purpose study investigate safety , tolerance , food effect , pharmacokinetics ( PK ) pharmacodynamics ( PD ) single multiple dos extend release ( XR ) formulation Centanafadine ( CTN ) Young Healthy participant .</brief_summary>
	<brief_title>A Phase 1 Study Investigate Safety , Tolerance , Food Effect , Pharmacokinetics Pharmacodynamics Single Multiple Doses Extended Release Formulations Centanafadine ( CTN ) Young Healthy Subjects</brief_title>
	<detailed_description>The study divide three part : A , B , C. Part A : Single Dose , extend release ( XR ) Formulation Selection . This part study single dose , open label , four-period crossover design group 16 healthy participant . Part B : Multiple Ascending Dose . Part B design assess effect multiple dose one formulation XR CTN . This part study double-blind , randomize , placebo-controlled design . Part C : Food Effect . Part C design determine effect food XR CTN . The XR formulation dose administer select review Part B data . This part open-label , two-period crossover design group 16 healthy participant .</detailed_description>
	<mesh_term>Attention Deficit Disorder Hyperactivity</mesh_term>
	<mesh_term>Hyperkinesis</mesh_term>
	<criteria>1 . Body weight within normal range height ( body mass index [ BMI ] 1930 kg/m2 inclusive ) ; 2 . Negative serum pregnancy test Screening negative urine pregnancy test Day 1 female child bear potential ; 3 . Women childbearing potential must agree use adequate ; contraception prior study entry , duration study participation , 90 day follow completion therapy ; 4 . Be general good health without clinically significant medical history ; 5 . Have clinical laboratory test result within laboratory reference range ; range clinically relevant acceptable Investigator Sponsor medical representative ; 6 . Negative Human Immunodeficiency Virus ( HIV ) , Hepatitis B Hepatitis C Screening test ; 7 . Able willing give write informed consent . 1 . Use following medication exclude participant : investigational compound within 30 day prior Screening ; antipsychotic , anxiolytic , sedativehypnotic medication within 30 day prior Screening ; antidepressant medication within 30 day prior Screening ; clonidine within 30 day prior Screening ; cough/cold preparation contain stimulants/sympathomimetic agent within 7 day prior Day 1 ; norepinephrine reuptake inhibitor , tomoxetine ( STRATTERA® ) within 30 day prior Day 1 ; antihypertensive agent , include diuretic , permit time prior study ; sedate antihistamine ( single preparation combination ) within 7 day prior Day 1 ; sympathomimetics , appetite suppressant , modafinil , methylphenidate , amphetamine pemoline within 7 day prior Day 1 ; Use counter medication within 7 day Investigational Product administration , exception simple analgesic paracetamol , oral nonsteroidal antiinflammatory agent oral contraceptive pill ( applicable ) ; Use herbal preparation melatonin prohibit discontinued prior Day 1 . The process discontinuing use herbal preparation melatonin prior Day 1 discretion Investigator ; 2 . A history , current evidence , suicidal ideation , base upon clinical interview Columbia Suicide Severity Rating Scale ( CSSRS ) ; 3 . A history know suspected seizure , spasm , infantile spasm , febrile convulsion , unexplained significant recent loss consciousness history significant head trauma loss consciousness family history ( first degree relative ) epilepsy seizure ( fit ) ; 4 . Subject known history hypertension Subject supine systolic blood pressure ( SBP ) ≥140 mm Hg diastolic blood pressure ( DBP ) ≥90 mm Hg . No one repeat measurement permit ; 5 . Subject known history orthostatic hypotension orthostatic blood pressure ( BP ) drop ≥20 mm Hg ( base drop supine stand [ 3 minute ] SBP ) Screening Day 1 ; Note : The eligibility criterion list exhaustive .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>Centanafadine</keyword>
	<keyword>Adult attention-deficit hyperactivity disorder</keyword>
	<keyword>Healthy participant</keyword>
</DOC>